Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
The US government has released newly negotiated prices for the second batch of medicines subject to Medicare drug price negotiations under the Inflation Reduction Act (IRA), with Astellas Pharma’s prostate cancer therapy Xtandi (enzalutamide) among them. The Centers for Medicare…
To read the full story
Related Article
- Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
- Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…